Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (2S,3R,4R,5S,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl-13C)tetrahydro-2H-pyran-3,4,5-triol-2,3,4,5,6-13C5
Purity: ≥98%
Formula Markup: C15[13C]6H21FO5S
Formula Weight: 410.4
Notes: Ipragliflozin-13C6 is intended for use as an internal standard for the quantification of ipragliflozin (Item No. 22287) by GC- or LC-MS. Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter).{49504} It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ; Item No. 13104), and nicotinamide (Item No. 11127).{49505} It decreases plasma and hepatic IL-6, TNF-α, chemokine (C-C motif) ligand 2 (CCL2), and C-reactive protein (CRP) levels in the same model when administered at a dose of 3 mg/kg per day for 28 days.
Deutsch
English
